Role of islatravir in HIV treatment and prevention: an update. Issue 4 (July 2022)

• Record Type: Journal Article
• Authors: Derbalah, Abdallah; Karpick, Hayley Christine; Maize, Holly; Skersick, Preston; Cottrell, Mackenzie; Rao, Gauri G.
• Is Part Of: Current opinion in HIV & AIDS. Volume 17:Issue 4(2022)
• Page Start: 240
• Page End: 246
• Publication Date: 2022-07
• Subjects: HIV -- antiretroviral therapy -- nucleoside reverse transcriptase translocation inhibitor -- islatravir -- long-acting oral and implantable; AIDS (Disease) -- Periodicals; HIV infections -- Periodicals; HIV Infections -- Periodicals; Acquired Immunodeficiency Syndrome -- Periodicals; Infections à VIH -- Périodiques; Sida -- Périodiques; AIDS (Disease); HIV infections; Periodicals; 616.9792005
• DOI: 10.1097/COH.0000000000000740
• Languages: English
• ISSNs: 1746-630X

Abstract

Abstract : Purpose of review: To summarize recent updates on the potential role of islatravir for HIV treatment and prevention. Recent findings: Islatravir is an investigational antiretroviral agent with unique pharmacologic properties that facilitate flexible dosing regimens. Islatravir has demonstrated potent antiviral activity and a high barrier to resistance when combined with doravirine and lamivudine. A simplified two-drug HIV treatment regimen of islatravir combined with doravirine has also demonstrated comparable efficacy to standard of care three-drug regimens. The long half-life and high potency of islatravir's active metabolite may support its use as a long-acting option for HIV preexposure prophylaxis (PrEP). A once monthly oral dose of islatravir maintains effective concentrations of its active metabolite over the entire dosing interval. Furthermore, an investigational implantable formulation has been projected to provide efficacious concentrations for at least a year and exhibits comparable distribution into vaginal and rectal tissues making it a promising PrEP option for male and female individuals. Islatravir has minimal risks of drug interactions as it is not a substrate, inducer, or inhibitor of major drug metabolizers and transporters. Finally, clinical trials demonstrate islatravir's favorable safety profile revealing only mild and transient adverse events. Summary: Leveraging the unique pharmacological properties of islatravir offers opportunities for simplified HIV treatment regimens and long-acting PrEP making it a valuable addition to the antiretroviral arsenal.